Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025International Journal of Molecular SciencesOpen Access

Treatment of Dyslipidemia in Patients with Type 1 Diabetes Mellitus: A Review of Current Evidence and Knowledge Gaps

View Full Paper
Ask AI
Bookmark
Share

Authors

VEViviana ElianADAlina DoritaDSDaniela Stegaru

Discussion

Loading...

Member takes

Overview

Review reveals limited T1D-specific evidence on dyslipidemia management, highlighting dyslipidemia treatment ambiguity.

Key Points

  • Statin therapy reduces cardiovascular risk by up to 25% in diabetes patients, though evidence for T1D is limited.
  • Each 1 mmol/L increase in LDL cholesterol increases cardiovascular risk by 35–50% in T1D cohorts.
  • International guideline recommendations show heterogeneity, emphasizing the need for targeted treatment strategies.
  • The uptake of statins in eligible adults with T1D remains below 50%, despite their cornerstone role in dyslipidemia management.

Cite This Study

Elian et al. (2025) studied this question.

synapsesocial.com/papers/68c23bd7b210217d64786f5ahttps://doi.org/10.3390/ijms26178558
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bridging the Gap between Evidence and Practice: Nationwide Retrospective Analysis of Lipid-Modifying Therapy Prescription Patterns in 5 Million Patients with Type 2 Diabetes Mellitus2025
  2. 2Remnant Cholesterol and Cardiovascular Risk in Adults With Type 1 Diabetes: A Nested Case–Control Study2025
  3. 3Dyslipidemia in Diabetes: Understanding the Role of Insulin in Lipid Metabolism2025 · 1 citations
  4. 4Remnant Cholesterol: From Pathophysiology to Clinical Implications in Type 1 Diabetes2025
  5. 5Understanding the Increasing Prevalence of Obesity in Patients With Type 1 Diabetes: Strategies for Improving Clinical Care2025